The current issue of the BMJ (9th April 2015) includes a quick resume of the actions to take when a patient presents with a high INR. Although this will be familiar to most of us, it is a good summary for anyone who needs an update.
The makers of a novel antidote that reverses the anticoagulant effects of the factor Xa inhibitors announced that the second part of a phase 3 study testing the agent met its primary end point. The antidote, an intravenous bolus of andexanet alfa (Portola Pharmaceuticals, San Francisco, CA), produced a "rapid reversal" of the anticoagulant effect of apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) in the ANNEXA-A study, according to the company.
A fantastic animated sequence which shows the structure and working of the human heart. Highly recommended.
An article in the current issue of the British Journal of Haematology considers the incidence, significance and treatment of Superficial Venous Thrombosis. This condition is often dismissed as benign and self-limiting, but can lead to more serious thrombotic consequences.
This new course from The University of Birmingham aims to give healthcare professionals the information they need to train and support patients who are self-monitoring oral anticoagulants.
Date: 24th February 2015